Loading…
Loading…
are you guys starting to see off-label use in the frontline in advance of formal approval given the very positive readouts and the NCCN recommendation
for anito-cel, could the filing happen any day or in the very near future? What is left that's required for the filing
whether you expect the early prescriptions to trend linearly from here or if it's still very early in what is expected to be a more of an exponential launch curve
For Trodelvy, is the lower demand quarter over quarter due to bladder coming out or lower demand in breast
what led to the 16% year-over-year PrEP market growth and acceleration for 2024 that you highlighted